Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis in patients with diabetes and liver dysfunction

Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis in patients with diabetes and liver dysfunction - Multicenter study of inhibitory effect of DPP-4 inhibitor (and/ ARB) on hepatic fibrosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008068

Enrollment

100

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Liver dysfunction Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients over 20 years old 2) type 2 diabetes and ALT> 30

Exclusion criteria

Exclusion criteria: 1) Patients with co-infection with hepatitis B virus 2) Patients with co-infection with hepatitis C virus 3) Patients with autoimmune hepatitis, primary biliary cirrhosis 4) Patients with alcohol addict (more than 20g/day) 5) Patients with insulin therapy

Design outcomes

Primary

Measure	Time frame
Suppression of hepatic fibrosis (Markers of fibrosis, such as hyaluronic acid, type IV collagen7S, and P3P. The degree of liver fibrosis by liver biopsy)	—

Secondary

Measure	Time frame
Improvement of liver function (TP, Alb, ChE, AST, ALT, LDH, ALP, r-GTP, T-Bil)	—

Countries

Japan

Contacts

Public ContactRyuichi Noguchi

Nara Medical University Third department of Internal Medicine

3naika@naramed-u.ac.jp0744-22-3051

Outcome results